Running title: Ubiquitination of α-Synuclein. 
INTRODUCTION
Lewy bodies (LBs) and related neuritic changes (Lewy neurites; LNs) are the defining neuropathological characteristics of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The discovery of point mutations in the α-synuclein gene in some pedigrees with autosomal-dominantly inherited familial PD (1, 2) , together with the identification of α-synuclein as the major component of abnormal filaments in LBs and LNs in the brains of patients with PD and DLB (3, 4, 5, 6) , strongly implicated α-synuclein in the pathogenesis of these neurodegenerative disorders.
Immunohistochemical and biochemical studies using anti-α-synuclein antibodies revealed that α-synuclein is deposited in other types of filamentous inclusions including glial or neuronal cytoplasmic inclusions (GCIs and NCIs) in multiple system atrophy (MSA) (7, 8, 9) and Lewy body-like inclusions and dystrophic neurites in Hallervorden-Spatz disease (HSD) (10, 11) , leading to the collective nomenclature of "α-synucleinopathies" for these disorders. Recent biochemical studies have shown that the full-length α-synuclein is deposited as abnormal filaments (9, 12) , which are recovered in detergent-(i.e. Triton X and Sarkosyl) insoluble fractions of brains of patients with synucleinopathy, but not in control brains (13, 14, 15) . We and others have shown that insoluble α-synuclein from synucleinopathy brains as well as in vitro assembled filaments from recombinant α-synuclein are highly resistant to proteinase K, leaving the middle portion of α-synuclein as core structure of the filaments (15, 16) .
We have further shown by mass spectrometry and specific antibodies that the α-synuclein deposited in DLB brains as well as other synucleinopathies is phosphorylated at Ser129 (17) . Quantitative immunoblot analyses have further shown that >90 % of the insoluble α-synuclein in DLB brains is phosphorylated, whereas 4 % of normal α-synuclein, is phosphorylated at Ser129, suggesting that the extensive phosphorylation of α-synuclein is a pathological event (17) . Additional posttranslational modifications of α-synuclein, including tyrosine nitration (18) or Oglycosylation (19) have been reported in synucleinopathies and autosomal recessive juvenile parkinsonism (AR-JP), respectively.
In addition to α-synuclein, immunoreactivities for a number of proteins, including ubiquitin (20) , neurofilament (21), synphilin-1 (22) , parkin (19) , MAP1B (23), etc., have been shown by immunohistochemistry in LBs and related structures.
Among these proteins, ubiquitin has been known to be most constantly and robustly immunopositive in LBs, GCIs and other related lesions, together with α-synuclein. The presence of ubiquitin in intracellular inclusions in synucleinopathies suggests that abnormally aggregated or misfolded proteins are targeted for ubiquitination in these inclusions, in a similar fashion to tau in neurofibrillary tangles of Alzheimer's disease (24, 25) . Recently, Shimura et al reported that glycosylated α-synuclein (αSp22) can readily be multiubiquitinated by parkin that functions as E3 ubiquitin ligase in vitro (19) . However, the target protein for ubiquitination in synucleinopathy lesions including LBs has been totally unknown. Here we show immunochemical and proteinchemical evidence that full-length, phosphorylated α-synuclein is one of the target proteins for ubiquitination in synucleinopathies, and that these α-synuclein polypeptides undergo mono-and di-ubiquitination.
EXPERIMENTAL PROCEDURES
Antibodies -Mouse monoclonal antibodies (mAbs) Syn102 (epitope location on α-synuclein: residues 131-140) (9, 26) , LB509 (115-121/122) (5, 27 ) and a rabbit polyclonal antibody 259 (104-119) (5) were used as immunoprobes that recognize α-synuclein in a phosphorylation-independent manner. A rabbit polyclonal antibody PSer129 specifically recognizes α-synuclein phosphorylated at Ser129 (17) . Mouse mAbs1510 (28) , and 5-25 (29) and a rat mAb DF2 (24) Sarkosyl-insoluble α-synuclein was prepared as described (15, 17) with slight modifications. Briefly, frozen brain tissues from patients with DLB, MSA and HSD, as well as from control individuals were homogenized in a 10 fold volume of buffer A (10 mM Tris, pH 7.5, 1 mM EGTA, 1 mM DTT, 10 % sucrose) and centrifuged at 14,000 rpm (23,000 x g) for 15 min. The pellets were then extracted in buffer A containing 1 % Triton X-100, and centrifuged at 386,000 x g for 20 min. The resultant pellets were subsequently homogenized in buffer A containing 1 % Sarkosyl, incubated at room temperature for 1 hr and centrifuged at 386,000 x g for 20 min. The Sarkosylinsoluble pellets were solubilized in 2 % SDS, spun at 23,000 x g for 10 min, and the supernatants were separated by SDS-PAGE and analyzed by immunoblotting.
Preparation of ubiquitin-conjugated α-synuclein -In vitro ubiquitination of α-synuclein was performed according to the same methods described previously (32) with minor modifications. Briefly, 20 µg of human recombinant α-synuclein and 2 µg 
RESULTS

Immunochemical identification of ubiquitinated α-synuclein in α-synucleinopathies -
To biochemically characterize the changes in α-synuclein deposited in the brains of patients with DLB, MSA or HSD, we sequentially extracted frozen brain tissues with Tris-HCl buffer, 1 % Triton X-100, 1 % Sarkosyl and 2 % SDS, and analyzed the solubilized proteins by immunoblotting with anti-α-synuclein antibodies. Immunoblots of Sarkosyl-insoluble fractions showed a couple of α-synuclein immunoreactive bands exclusively in DLB, MSA and HSD, but not in control brains (Fig. 1, 2) . The major immunoreactive band with an apparent molecular weight of 15 kDa on Tris-tricine gel system was also immunoreactive with the phosphorylation dependent anti-α-synuclein antibody anti-PSer129 and co-migrated with human recombinant α-synuclein as well as Tris-soluble normal α-synuclein, as we have previously described (Fig 2) . In addition to the 15 kDa band, anti-α-synuclein antibodies detected a couple of minor bands migrating at higher molecular weight ranges of 22 and 29 kDa in the Sarkosylinsoluble fractions of DLB brains (Fig 1) . The 22 kDa and 29 kDa polypeptides were observed in all the synucleinopathy brains (i.e., DLB, MSA and HSD) examined in this study, but were exclusively detected in the Sarkosyl-insoluble fractions, and the intensities of these bands apparently correlated with those of the 15 kDa band (Fig.   1,2 ). These 22 kDa and 29 kDa bands were also immunoreactive for anti-PSer129, suggesting that the higher molecular weight α-synuclein-related polypeptides are phosphorylated. We next investigated whether the higher molecular weight bands represent α-synuclein multimers or alternatively they may correspond to α-synuclein with some specific post-translational modifications. Judging from the size of these polypeptides, we hypothesized that the 22 kDa and 29 kDa bands may correspond to mono-and di-ubiquitinated α-synuclein, respectively. To test these possibilities, we analysed the Sarkosyl-insoluble fractions of DLB brains with an anti-ubiquitin monoclonal antibody 1510 (mAb1510). Mab 1510 strongly labeled the 22 kDa and 29 kDa bands as well as the smearing substances at higher molecular weight ranges in DLB brains, suggesting that these bands represent ubiquitinated forms of α-synuclein.
In vitro Ubiquitination of α-synuclein -To examine our speculation if the 22 and 29 kDa bands represent ubiquitinated α-synuclein, we ubiquitinated α-synuclein using ubiquitin ligase fractions from rabbit reticulocytes in vitro, and compared the mobilities of in vitro ubiquitinated α-synuclein on SDS-PAGE with those derived from DLB and other synucleinopathy brains. On immunoblots of recombinant α-synuclein itself or with ubiquitin, a major 15 kDa band (corresponding to α-synuclein monomer) and a minor 29 kDa band, the latter presumably representing α-synuclein dimer, were detected with an anti-α-synuclein mAb Syn102 (Fig 2A) . Immunoblot analysis of ubiquitin itself with anti-ubiquitin mAb also showed a similar pattern with a major 7 kDa (ubiquitin monomer) and a minor 15 kDa band, the latter presumably representing ubiquitin dimer (Fig 2A) . In contrast, when recombinant α-synuclein was incubated with ubiquitin and the ubiquitin ligase fraction, both Syn102-and mAb 1510-positive bands appeared at 22, 29 and 36 kDa (Fig 2A) . None of these bands were detected in reaction mixtures of the ubiquitin ligase fraction without α-synuclein and Ub (data not shown). Considering the molecular mass of Ub comprised of 76 amino acids, it is reasonable to speculate that these 22, 29 and 36 kDa bands represent mono-, di-and tri-ubiquitinated forms of α-synuclein. The 22 and 29 kDa bands (presumably monoand di-ubiquitinated α-synuclein, respectively) derived from in vitro ubiquitination of α-synuclein co-migrated at positions identical to those of the 22 and 29 kDa polypeptides recovered from Sarkosyl-insoluble fractions from DLB, MSA and HSD brains on immunoblots (Fig 2B) , suggesting that the 22 and 29 kDa bands from DLB, MSA and HSD brains correspond to mono-and di-ubiquitinated forms of phosphorylated α-synuclein, respectively. Notably, the migration position of the 29 kDa α-synuclein dimer was almost identical to that of di-ubiquitinated α-synuclein (Fig 2A) . (Fig 4A) , and ubiquitin has one Met at the N-terminus.
CNBr treatment of the Sarkosyl-insoluble
When we treated the Sarkosyl-insoluble fractions from HSD brains that was most abundant in insoluble α-synuclein with CNBr, separated the digests by SDS-PAGE and analyzed by immunoblotting with an anti-α-synuclein antibody 259 or an anti-Ub mAb DF2, polypeptides migrating at 19 kDa and 26 kDa were observed instead of the 22 and 29 kDa bands (Fig 3) . The reduction of the molecular weights of corresponding bands by ~ 3 kDa was almost equivalent to the sum of the N-and C-terminal portions (i.e., 5 and 24 amino acids, respectively) that are cleaved by CNBr treatment. (Fig 3, 4) Notably, the anti-α-synuclein (259) positive-but anti-Ub negative, 25 kDa band appeared after CNBr treatment (Fig 3) . This band may represent a truncated form of α-synuclein dimer derived from the 29 kDa full-length dimer, because the reduction in the molecular weight of the α-synuclein dimer by CNBr treatment (equivalent to 58 amino acids) is predicted to be larger than that of ubiquitinated α-synuclein (29 + 1 amino acids). Immunoblots analysis of the CNBr treated Sarkosyl-insoluble pellet from a MSA brain also showed patterns similar to those of DLB and HSD brains.
These results supported our view that the 22 kDa band in the insoluble fractions of synucleinopathy brains represents mono-ubiquitinated α-synuclein, and the 29 kDa band may be the mixture of di-ubiquitinated α-synuclein and α-synuclein dimer. It is consistent with the fact that the ubiquitin acceptable lysine residues are located in the N-terminal to middle portion of α-synuclein (residues 6 -115) rather than in the extreme N-or C-terminal regions of α-synuclein. 
Protein sequencing of the
DISCUSSION
During the analysis of post-translational modifications (e.g., phosphorylation) of α-synuclein in synucleinopathy brains, we found two α-synucleinpositive polypeptides migrating at 22 and 29 kDa in addition to the major 15 kDa band, which were immunoreactive to both phosphorylation-independent and PSer129-specific anti-α-synuclein antibodies. These 22 kDa and 29 kDa bands were also immunoreactive to three different anti-ubiquitin antibodies (i.e., mAbs 1510, DF2 and 5-25). Furthermore, these bands aligned on SDS-PAGE with the in vitro ubiquitinated α-synuclein bands that presumably correspond to mono-and di-ubiquitinated α-synuclein, respectively. The 22 kDa and 29 kDa bands shifted to positions at 19 kDa and 26 kDa after treatment with CNBr, which were also immunopositive for both an anti-α-synuclein antibody 259 and anti-ubiquitin antibodies, providing further evidence that these represent ubiquitinated forms of α-synuclein. kDa bands to those of 15 kDa α-synuclein monomer in Sarkosyl-insoluble fractions from DLB brains was approximately 1 : 10, suggesting that mono-or di-ubiquitinated α-synuclein may be a minor species, although the high molecular weight smearing substances or SDS-insoluble fractions may contain multi-ubiquitinated forms of α-synuclein. Indeed, support for this notion comes from our previous attempts to raise mAbs to LBs, which yielded an antibody (LB112) that specifically reacted with multiubiquitin chains in LBs, and this provided the first biochemical evidence suggesting a role for ubiquitination in LB formation (33) . Since the mid-portion of α-synuclein harbors 15 Lys residues, further protein chemical analysis is required to locate the exact position of ubiquitin-ligated Lys residue.
As to the possible di-ubiquitinated form (i.e., 29 kDa) of α-synuclein, it is unknown whether the two ubiquitin molecules are conjugated to two different lysine residues, or alternatively, only one Lys residue of α-synuclein is ubiquitinated and the second ubiquitin is conjugated to the initial one, forming a "T-shaped" di-ubiquitin moiety. It has been shown that tau in paired helical filaments (PHFs) of Alzheimer brains are ubiquitinated (24, 25) : our previous protein chemical analysis have identified a couple of ubiquitination sites within the microtubule binding domain of tau that comprise the core structure of PHFs (25) . Importantly, ~70% of ubiquitin conjugated to tau in PHF were present in mono-ubiquitinated form, although some multiubiquitin chains also were detected. Taken together with our previous observation that the core structure of α-synuclein filaments is composed of residues 31-109, it is possible to speculate that Lys residues within or flanking positions of core structure of insoluble filaments are prone to undergo ubiquitination by some specific ubiquitin ligase system that recognizes abnormally fibrillized proteins, although an effective formation of multi-ubiquitin chains is interfered by unknown mechanism, allowing the progressive deposition of oligo-ubiquitinated proteins that are less effectively targeted to proteasome degradation.
Our data suggest that mono-or di-ubiquitinated α-synuclein in synucleinopathy brains is also phosphorylated at Ser129. Although it is well known that protein phosphorylation triggers ubiquitination of a number of short-lived proteins (e.g., cyclin or β-catenin) (34) , it is unknown whether the phosphorylation at Ser129 of α-synuclein, that is specifically upregulated and may promote deposition of insoluble 
